Zobrazeno 1 - 10 of 73 pro vyhledávání: '"Sandhöfer, N."'
2
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging
Autor: Vick, B., Rothenberg, M., Sandhöfer, N., Carlet, M., Finkenzeller, C., Krupka, C., Grunert, M., Trumpp, A., Corbacioglu, S., Ebinger, M., Andre, M.C., Hiddemann, W., Schneider, S., Subklewe, M., Metzeler, K.H., Spiekermann, K., Jeremias, I.
Publikováno v: PLoS ONE 10:e0120925 (2015)
Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with poor outcome. Adequate model systems are required for preclinical studies to improve understanding of AML biology and to develop novel, rational treatment approac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3474::c3d3d129b2c66f63340e53e9962d64d2
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=43909
Zobrazit plný text záznamu
4
Akademický článek
In vivo monitoring of leukemia-niche interactions in a zebrafish xenograft model.
Autor: Arner, Anja1 (AUTHOR), Ettinger, Andreas2 (AUTHOR), Blaser, Bradley Wayne3 (AUTHOR), Schmid, Bettina4 (AUTHOR), Jeremias, Irmela1,5 (AUTHOR), Rostam, Nadia1,6 (AUTHOR), Binder-Blaser, Vera1 (AUTHOR) vera.binder-blaser@med.uni-muenchen.de
Publikováno v: PLoS ONE. 8/30/2024, Vol. 19 Issue 8, p1-18. 18p.
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.
Autor: Sandhöfer N; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Metzeler KH; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Kakadia PM; Department of Molecular Medicine and Pathology, University of Auckland, New Zealand., Pasalic Z; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Hiddemann W; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Neusser M; Institute of Human Genetics, University Hospital, Ludwig-Maximilians-University, Munich, Germany., Steinlein O; Institute of Human Genetics, University Hospital, Ludwig-Maximilians-University, Munich, Germany., Fiegl M; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Subklewe M; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Spiekermann K; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Bohlander SK; Department of Molecular Medicine and Pathology, University of Auckland, New Zealand., Schneider S; Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig-Maximilians-University, Munich, Germany., Braess J; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany.
Publikováno v: Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2017 Aug; Vol. 56 (8), pp. 632-638. Date of Electronic Publication: 2017 May 19.
Zobrazit plný text záznamu
7
Akademický článek
503: Novel FLT3 mutation shows dominant negative effects on the wild-type FLT3 receptor
Autor: Bauer, J., Sandhöfer, N., Hiddemann, W., Spiekermann, K.
Publikováno v: In European Journal of Cancer July 2014 50 Supplement 5:S121-S121
Zobrazit plný text záznamu
8
Akademický článek
The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.
Autor: Sandhöfer N; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Bauer J; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Reiter K; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Dufour A; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Rothenberg M; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Konstandin NP; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Zellmeier E; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Tizazu B; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Greif PA; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Metzeler KH; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany., Hiddemann W; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Polzer H; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Spiekermann K; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Publikováno v: Scientific reports [Sci Rep] 2016 Jun 27; Vol. 6, pp. 28032. Date of Electronic Publication: 2016 Jun 27.
Zobrazit plný text záznamu
9
Akademický článek
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Autor: Vick B; Group Apoptosis, Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany., Rothenberg M; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany., Sandhöfer N; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany; Clinical Cooperation Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Carlet M; Group Apoptosis, Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Finkenzeller C; Group Apoptosis, Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Krupka C; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany; Clinical Cooperation Group Immunotherapy, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Grunert M; Group Apoptosis, Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Trumpp A; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany., Corbacioglu S; Department of Pediatrics, University of Regensburg, Regensburg, Germany., Ebinger M; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Hematology/Oncology, University Children's Hospital, Eberhard Karls Universität, Tuebingen, Germany., André MC; Department of Pediatric Hematology/Oncology, University Children's Hospital, Eberhard Karls Universität, Tuebingen, Germany; Department of Pediatric Intensive Care Medicine, University Children's Hospital (UKBB), Basel, Switzerland., Hiddemann W; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany; Clinical Cooperation Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Schneider S; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany., Subklewe M; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany; Clinical Cooperation Group Immunotherapy, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Metzeler KH; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany; Clinical Cooperation Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Spiekermann K; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany; Clinical Cooperation Group Leukemia, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany., Jeremias I; Group Apoptosis, Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Oncology, Dr von Haunersches Kinderspital, Ludwig Maximilians-Universität (LMU), Munich, Germany.
Publikováno v: PloS one [PLoS One] 2015 Mar 20; Vol. 10 (3), pp. e0120925. Date of Electronic Publication: 2015 Mar 20 (Print Publication: 2015).
Zobrazit plný text záznamu
10
Akademický článek
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities.
Autor: Wiese, Wojciech1 (AUTHOR) wojciech.wiese@stud.umed.lodz.pl, Barczuk, Julia1 (AUTHOR) julia.barczuk@stud.umed.lodz.pl, Racinska, Olga1 (AUTHOR) olga.racinska@stud.umed.lodz.pl, Siwecka, Natalia1 (AUTHOR) natalia.siwecka@stud.umed.lodz.pl, Rozpedek-Kaminska, Wioletta1 (AUTHOR) wioletta.rozpedek@umed.lodz.pl, Slupianek, Artur2 (AUTHOR) aslupian@temple.edu, Sierpinski, Radoslaw3 (AUTHOR) r.sierpinski@uksw.edu.pl, Majsterek, Ireneusz1 (AUTHOR) ireneusz.majsterek@umed.lodz.pl
Publikováno v: Cancers. Nov2023, Vol. 15 Issue 21, p5297. 18p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje